Researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), have developed a swallowable nanoscale delivery platform designed to transport therapeutic enzymes through the stomach’s acidic environment and activate a cancer-killing reaction at tumor sites. Early preclinical findings suggest that the approach may offer a new strategy for treating gastric cancer more precisely while reducing damage to healthy tissue.

The preclinical study, published in the Journal of Nanobiotechnology, was led by associate professor Chester Lee Drum, Department of Medicine and the Cardiovascular-Metabolic Disease Translational Research Program (TRP), NUS Medicine, together with co-first authors Dr. Muthu Kumaraswamy Shanmugam and Dr. Girish Vallerinteavide Mavelli, both senior research fellows at the Department of Medicine, NUS Medicine.